文献速递血液净化与透析慢性肾脏病

扩展血液透析(Theranova透析器)对起始长期血透患者残余肾功能的影响:随机对照试验

Expanded Hemodialysis with Theranova Dialyzer and Residual Kidney Function in Patients Starting Long-Term Hemodialysis: A Randomized Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2025-03-04

这项随机对照试验纳入80例起始长期血液透析的患者,比较Theranova 400与高通量透析器治疗12个月的效果。主要结局为尿素和肌酐清除率均值确定的GFR变化,结果显示Theranova组GFR下降幅度显著小于高通量组。Theranova组中分子毒素和炎症因子降低更明显,肾损伤标志物升高更少。

要点

  • Theranova组12个月GFR下降较小,组间最小二乘均值差为−1.4(95%CI −2.4至−0.5)ml/min/1.73m²。
  • Theranova组24小时尿量在9个月时维持更好,但12个月时无差异。
  • 两组住院率和死亡率无差异。

核心结论

  • 在起始长期血液透析的患者中,使用Theranova透析器进行扩展血液透析可能延缓残余肾功能下降。

研究设计与样本

  • 随机对照试验,纳入80例起始长期血液透析的患者,平均年龄63岁(标准差12),男性52例(65%)。
  • 患者随机接受Theranova 400或表面积相近的高通量透析器治疗,持续12个月。
  • 主要结局为12个月内GFR变化,以尿素和肌酐清除率均值确定;次要结局包括24小时尿量、中分子和肾损伤标志物变化。

主要发现

  • 12个月内Theranova组GFR下降显著小于高通量组,最小二乘均值差为−1.4(95%CI −2.4至−0.5)ml/min/1.73m²。
  • Theranova组24小时尿量在9个月时维持优于高通量组,但12个月时无差异。
  • Theranova组κ/λ游离轻链、TNF-α和生长分化因子-15的下降率高于高通量组。
  • Theranova组肾损伤标志物IGF结合蛋白7的升高幅度减弱。
  • 两组住院率和死亡率无差异。

临床怎么用

  • 对于起始长期血液透析的患者,可考虑使用Theranova透析器进行扩展血液透析以减缓残余肾功能下降。
  • 需关注Theranova对中分子毒素和炎症因子的清除优势,但12个月时尿量获益不持续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: This randomized controlled trial evaluated the effect of expanded hemodialysis on preserving residual kidney function in patients starting treatment with long-term hemodialysis. The expanded hemodialysis group with Theranova dialyzer showed smaller decrease in GFR than the high-flux group over 12 months. The Theranova group had a larger reduction in middle molecules and inflammatory cytokines and smaller increases in kidney injury markers. BACKGROUND: Expanded hemodialysis using a medium cutoff dialyzer improves the clearance of middle-molecular toxins compared with conventional hemodialysis. This study evaluated the effect of expanded hemodialysis on preserving residual kidney function in patients starting treatment with long-term hemodialysis. METHODS: Patients who initiated long-term hemodialysis were randomized to receive dialysis with either a Theranova 400 (Baxter) or a high-flux dialyzer with a similar surface area over 12 months. The primary outcome was a change in GFR over 12 months, as determined by the mean of urea and creatinine clearance. The secondary outcome was a change in 24-hour urine volume, middle molecules, and kidney injury markers. RESULTS: A total of 80 patients on hemodialysis (mean age [SD]: 63 [12] years; male: 52 [65%]) underwent randomization. Over 12 months, the Theranova group demonstrated a significantly smaller decrease in GFR than the high-flux group (least squares mean difference of change [95% confidence interval], −1.4 [−2.4 to −0.5] ml/min per 1.73 m2). Theranova maintained greater 24-hour urine volume until 9 months, not at 12 months, compared with the high-flux dialyzer. The reduction ratio for κ/λ free light chains, TNF-α, and growth differentiation factor-15 was higher in the Theranova group than in the high-flux group. The increase in the kidney injury marker, IGF-binding protein 7, was attenuated in the Theranova group. Hospitalization rate and mortality did not differ between the two groups. CONCLUSIONS: This trial suggests that expanded hemodialysis using the Theranova dialyzer slowed decline in residual kidney function compared with a high-flux dialyzer in patients starting treatment with long-term hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: Theranova versus High-flux Dialyzer on Preservation of Residual Renal Function, NCT04211571.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lim JH, Seo YJ, Jeon Y, et al. Expanded Hemodialysis with Theranova Dialyzer and Residual Kidney Function in Patients Starting Long-Term Hemodialysis: A Randomized Controlled Trial. J Am Soc Nephrol. 2025. PMID: 40036081. doi:10.1681/ASN.0000000655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。